Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Pooled Safety Analysis from Phase I and II Studies for Patients with Relapsed Indolent Non-Hodgkin's Lymphoma Treated with Intravenous Copanlisib

Pier Luigi Zinzani, MD PhD, Amita Patnaik, MD FRCP, Franck Morschhauser, MD PhD, Gilles Andre Salles, MD PhD, Armando Santoro, MD, Luigina Mollica, MD PhD, Krimo Bouabdallah, MD, David Cunningham, MD FRCP, Sirpa Leppa, MD, George Follows, MA, PhD FRCP, FRCPath, BM, BCh, Alice Benson, PhD, Peter Bonata, PhD, Isabelle Genvresse, MD, Ashok Miriyala, MD, Aruna Mehra, MD, Jose Garcia-Vargas, MD, Barrett H. Childs, MD, Martin Dreyling, MD PhD

Blood (2017) 130 (Supplement 1): 4042.

https://doi.org/10.1182/blood.V130.Suppl_1.4042.4042

Published: 2017

Journal Articles

Establishment and Characterization of a Patient-Derived Model of ALK-Positive Anaplastic Large Cell Lymphoma

Michael J Wick, PhD, Elena Helman, PhD, Teresa L Vaught, DVM, Monica Farley, BS, Drew W Rasco, MD, Lon Smith, MD, Anthony Tolcher, MD, Amita Patnaik, MD, Michael Clark, PhD, Kyriakos P Papadopoulos, MD

Blood (2015) 126 (23): 5121.

https://doi.org/10.1182/blood.V126.23.5121.5121

Published: 2015

Journal Articles

ASN002: A Potent Dual SYK/JAK Inhibitor Currently in a Phase I/II Study Shows Strong Antitumor Activity in Preclinical Studies

Niranjan S. Rao, PhD, Sanjeeva Reddy, PhD, Gupta Sandeep, PhD, Nitin K Damle, PhD, Venkatesan M Aranapakam, PhD, Scott Thompson, PhD, Roger Smith, PhD, Terry Plasse, MD, Penelope Bristow, MS, Anthony Tolcher, MD, Kyriakos P Papadopoulos, MD, Amita Patnaik, MD, Drew W Rasco, MD

Blood (2015) 126 (23): 4009.

https://doi.org/10.1182/blood.V126.23.4009.4009

Published: 2015

Journal Articles

Phase I Study of Intravenous PI3K Inhibitor Bay 80–6946: Preliminary Activity in Patients with Relapsed Non-Hodgkin Lymphoma (NHL) Treated in an MTD Expansion Cohort

Amita Patnaik, MD, Ramesh K Ramanathan, MD, Leonard Joseph Appleman, MD, PhD, Anthony W Tolcher, MD, FRCP, James M Mountz, MD, PhD, Muralidhar Beerham, MD, Glen J Weiss, MD, Drew W Rasco, MD, Michael T Lotze, MD, Frederico GS Toledo, MD, Matthew J Oborski, MS, Prabhu Rajagopalan, PhD, Michael Jeffers, PhD, Andrea Kelly, Isabelle Genvresse, MD

Blood (2012) 120 (21): 3704.

https://doi.org/10.1182/blood.V120.21.3704.3704

Published: 2012

Journal Articles

A Phase I Dose Expansion Cohort Study of the Safety, Pharmacokinetics and Pharmacodynamics of SAR245409 (S09), An Orally Administered PI3K/mTOR Inhibitor, in Patients with Lymphoma

Kyriakos P Papadopoulos, MD, Pau Abrisqueta, MD, Glenda Chambers, BSN, RN, OCN, CCRC, Drew Rasco, MD, Amita Patnaik, Josep Tabernero, MD, Kanya Rajangam, MD, PhD, Kevin Rockich, Coumaran Egile, Adrianne Kelly, MD, Yi Xu, Joanne Lager, MD, Julie M Vose, MD

Blood (2011) 118 (21): 1608.

https://doi.org/10.1182/blood.V118.21.1608.1608

Published: 2011

NARROW

Pooled Safety Analysis from Phase I and II Studies for Patients with Relapsed Indolent Non-Hodgkin's Lymphoma Treated with Intravenous Copanlisib

Establishment and Characterization of a Patient-Derived Model of ALK-Positive Anaplastic Large Cell Lymphoma

ASN002: A Potent Dual SYK/JAK Inhibitor Currently in a Phase I/II Study Shows Strong Antitumor Activity in Preclinical Studies

Phase I Study of Intravenous PI3K Inhibitor Bay 80–6946: Preliminary Activity in Patients with Relapsed Non-Hodgkin Lymphoma (NHL) Treated in an MTD Expansion Cohort

A Phase I Dose Expansion Cohort Study of the Safety, Pharmacokinetics and Pharmacodynamics of SAR245409 (S09), An Orally Administered PI3K/mTOR Inhibitor, in Patients with Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Pooled Safety Analysis from Phase I and II Studies for Patients with Relapsed Indolent Non-Hodgkin's Lymphoma Treated with Intravenous Copanlisib

Establishment and Characterization of a Patient-Derived Model of ALK-Positive Anaplastic Large Cell Lymphoma

ASN002: A Potent Dual SYK/JAK Inhibitor Currently in a Phase I/II Study Shows Strong Antitumor Activity in Preclinical Studies

Phase I Study of Intravenous PI3K Inhibitor Bay 80–6946: Preliminary Activity in Patients with Relapsed Non-Hodgkin Lymphoma (NHL) Treated in an MTD Expansion Cohort

A Phase I Dose Expansion Cohort Study of the Safety, Pharmacokinetics and Pharmacodynamics of SAR245409 (S09), An Orally Administered PI3K/mTOR Inhibitor, in Patients with Lymphoma

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only